BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yashiro M, Qiu H, Hasegawa T, Zhang X, Matsuzaki T, Hirakawa K. An EGFR inhibitor enhances the efficacy of SN38, an active metabolite of irinotecan, in SN38-refractory gastric carcinoma cells. Br J Cancer. 2011;105:1522-1532. [PMID: 21997136 DOI: 10.1038/bjc.2011.397] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Vayá I, Andreu I, Lence E, González-Bello C, Consuelo Cuquerella M, Navarrete-Miguel M, Roca-Sanjuán D, Miranda MA. Characterization of Locally Excited and Charge-Transfer States of the Anticancer Drug Lapatinib by Ultrafast Spectroscopy and Computational Studies. Chemistry 2020;26:15922-30. [PMID: 32585059 DOI: 10.1002/chem.202001336] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Hamzehlou S, Momeny M, Zandi Z, Kashani B, Yousefi H, Dehpour AR, Tavakkoly-bazzaz J, Ghaffari SH. Anti-tumor activity of neratinib, a pan-HER inhibitor, in gastric adenocarcinoma cells. European Journal of Pharmacology 2019;863:172705. [DOI: 10.1016/j.ejphar.2019.172705] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
3 Wen F, Li Q. Treatment dilemmas of cetuximab combined with chemotherapy for metastatic colorectal cancer. World J Gastroenterol 2016; 22(23): 5332-5341 [PMID: 27340349 DOI: 10.3748/wjg.v22.i23.5332] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
4 He Y, Fang Z, Ge G, Jiang P, Jin H, Zhang W, Yang L. The Inhibitory Effect of 20( S )-Protopanaxatriol (ppt) Towards UGT1A1 and UGT2B7: Inhibition of UGTs by ppt. Phytother Res 2013;27:628-32. [DOI: 10.1002/ptr.4755] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
5 Zhang SL, Liu CL, Wang SP, Hao YJ, Wang YD, Li QS. Erlotinib increases sensitivity of MKN45 cells to radiotherapy. Shijie Huaren Xiaohua Zazhi 2012; 20(17): 1502-1508 [DOI: 10.11569/wcjd.v20.i17.1502] [Reference Citation Analysis]
6 Karas S, Etheridge AS, Nickerson DA, Cox NJ, Mohlke KL, Cecchin E, Toffoli G, Mathijssen RHJ, Forrest A, Bies RR, Innocenti F. Integration of DNA sequencing with population pharmacokinetics to improve the prediction of irinotecan exposure in cancer patients. Br J Cancer 2021. [PMID: 34703007 DOI: 10.1038/s41416-021-01589-2] [Reference Citation Analysis]
7 Ma Y, Wang B, Guo Y, Zhang Y, Huang S, Bao X, Bai M. Inhibition of miR-196a affects esophageal cancer cell growth in vitro. Biomedicine & Pharmacotherapy 2016;84:22-7. [DOI: 10.1016/j.biopha.2016.09.013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
8 Pesenti C, Gusella M, Sirchia SM, Miozzo M. Germline oncopharmacogenetics, a promising field in cancer therapy. Cell Oncol (Dordr) 2015;38:65-89. [PMID: 25573079 DOI: 10.1007/s13402-014-0214-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
9 Takahashi K, Tanaka M, Yashiro M, Matsumoto M, Ohtsuka A, Nakayama KI, Izumi Y, Nagayama K, Miura K, Iwao H, Shiota M. Protection of stromal cell-derived factor 2 by heat shock protein 72 prevents oxaliplatin-induced cell death in oxaliplatin-resistant human gastric cancer cells. Cancer Lett 2016;378:8-15. [PMID: 27157913 DOI: 10.1016/j.canlet.2016.05.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
10 Okines AF, Cunningham D. Trastuzumab: a novel standard option for patients with HER-2-positive advanced gastric or gastro-oesophageal junction cancer. Therap Adv Gastroenterol. 2012;5:301-318. [PMID: 22973416 DOI: 10.1177/1756283x12450246] [Cited by in Crossref: 30] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
11 Thomaidis T, Maderer A, Formentini A, Bauer S, Trautmann M, Schwarz M, Neumann W, Kittner JM, Schad A, Link KH, Rey JW, Weinmann A, Hoffman A, Galle PR, Kornmann M, Moehler M. Proteins of the VEGFR and EGFR pathway as predictive markers for adjuvant treatment in patients with stage II/III colorectal cancer: results of the FOGT-4 trial. J Exp Clin Cancer Res 2014;33:83. [PMID: 25272957 DOI: 10.1186/s13046-014-0083-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
12 Shao J, Xu Z, Peng X, Chen M, Zhu Y, Xu L, Zhu H, Yang B, Luo P, He Q. Gefitinib Synergizes with Irinotecan to Suppress Hepatocellular Carcinoma via Antagonizing Rad51-Mediated DNA-Repair. PLoS One 2016;11:e0146968. [PMID: 26752698 DOI: 10.1371/journal.pone.0146968] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]